生物Xcel 治疗学报告称,BXCL501的第二阶段成果很有希望,BXCL501是一种在美沙酮抑制剂期间对类阿片提取的潜在新治疗方法,其功效与Lucemyra相似或优于Lucemyra,其副作用较小,剂量时间表更简单。 BioXcel Therapeutics reports promising Phase 2 results for BXCL501, a potential new treatment for opioid withdrawal during methadone taper, showing efficacy comparable to or better than Lucemyra with fewer side effects and a simpler dosing schedule.

生物Xcel 治疗学报告称,其药物BXCL501在美沙酮抑制剂期间治疗类阿片提取的试验阶段2取得了积极结果,表明它可能比Lucemyra有效或更好,Lucemyra的剂量时间表较简单,副作用较少,包括没有镇静剂。 BioXcel Therapeutics reported positive Phase 2 trial results for its drug BXCL501 in treating opioid withdrawal during methadone taper, showing it may be as effective or better than Lucemyra with a simpler dosing schedule and fewer side effects, including no sedation. 这些发现支持早期的数据,并遵循BXCL501在治疗激动症方面取得的前期第三阶段成功. The findings support earlier data and follow a prior Phase 3 success for BXCL501 in treating agitation. 该公告在市场前贸易中提高了公司股票的12%以上,以1.65美元收盘,上升了3.13%。 The announcement boosted the company’s stock more than 12% in pre-market trading, closing at $1.65, up 3.13%.